Azithromycin versus standard care in patients with mild-to-moderate COVID-19 (ATOMIC2): an open-label, randomised trial-Reference-Cited by-同舟云学术

Azithromycin versus standard care in patients with mild-to-moderate COVID-19 (ATOMIC2): an open-label, randomised trial

Published:2021-10 Issue:10 Volume:9 Page:1130-1140
ISSN:2213-2600
Container-title:The Lancet Respiratory Medicine
language:en
Short-container-title:The Lancet Respiratory Medicine

Author:

Hinks Timothy S C,Cureton Lucy,Knight Ruth,Wang Ariel,Cane Jennifer L,Barber Vicki S,Black Joanna,Dutton Susan J,Melhorn James,Jabeen Maisha,Moss Phil,Garlapati Rajendar,Baron Tanya,Johnson Graham,Cantle Fleur,Clarke David,Elkhodair Samer,Underwood Jonathan,Lasserson Daniel,Pavord Ian D,Morgan Sophie,Richards Duncan

Funder

Pfizer Inc Boulder

Wellcome Trust

University of Oxford

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine

Reference31 articles.

1. Azithromycin in viral infections;Oliver;Rev Med Virol,2021

2. In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication;Touret;Sci Rep,2020

3. Macrolides in critically ill patients with Middle East respiratory syndrome;Arabi;Int J Infect Dis,2019